Cargando…

Efficacy and safety of primary surgery with postoperative radiotherapy in head and neck mucosal melanoma: a single-arm Phase II study

BACKGROUND: There still remains no well-established treatment strategy for head and neck mucosal melanoma (HNMM). We aim to evaluate the effectiveness and safety of primary surgery with postoperative radiotherapy for this disease. PATIENTS AND METHODS: A single-arm, Phase II clinical trial was condu...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Ji-Jin, Zhang, Fan, Zhang, Guang-Shun, Deng, Xiao-Wu, Zhang, Wang-Jian, Lawrence, Wayne R, Zou, Lu, Zhang, Xiao-Shi, Lu, Li-Xia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298389/
https://www.ncbi.nlm.nih.gov/pubmed/30588103
http://dx.doi.org/10.2147/CMAR.S185017
_version_ 1783381309416013824
author Yao, Ji-Jin
Zhang, Fan
Zhang, Guang-Shun
Deng, Xiao-Wu
Zhang, Wang-Jian
Lawrence, Wayne R
Zou, Lu
Zhang, Xiao-Shi
Lu, Li-Xia
author_facet Yao, Ji-Jin
Zhang, Fan
Zhang, Guang-Shun
Deng, Xiao-Wu
Zhang, Wang-Jian
Lawrence, Wayne R
Zou, Lu
Zhang, Xiao-Shi
Lu, Li-Xia
author_sort Yao, Ji-Jin
collection PubMed
description BACKGROUND: There still remains no well-established treatment strategy for head and neck mucosal melanoma (HNMM). We aim to evaluate the effectiveness and safety of primary surgery with postoperative radiotherapy for this disease. PATIENTS AND METHODS: A single-arm, Phase II clinical trial was conducted at Sun Yat-Sen University Cancer Center. Patients with nonmetastatic, histologically proven HNMM were prospectively enrolled. Patients received primary surgery followed by intensity-modulated radiotherapy with an equivalent dose at 2 Gy per fraction of 65–70 Gy to CTV1 (high-risk regions including tumor bed) and 50–55 Gy to CTV2 (low-risk regions). Additional use of adjuvant chemotherapy (AC) depended on consultation from a multidisciplinary team. This trial is registered with ClinicalTrials.gov, number NCT03138642. RESULTS: A total of 33 patients were enrolled and analyzed between July 2010 and November 2016. There were 18 (54.5%) patients with T3 disease and 15 (45.5%) patients with T4a disease. The median age at diagnosis was 58 years (range 27–83 years), and 61% of the cohort were males. The overall median follow-up duration was 25.3 months (range 5.3–67.1 months). The 3-year overall survival (OS), local relapse-free survival (LRFS), regional relapse-free survival (RRFS), and distant metastasis-free survival (DMFS) rates were 44.4, 91.7, 78.1, and 41.7%, respectively. Patients with T4a disease showed significantly inferior OS (P=0.049) and DMFS (P=0.040) than those with T3 disease. Prophylactic neck radiation (PNR) was nearly associated with superior RRFS (P=0.078). However, there was no significant difference in OS, LRFS, RRFS, and DMFS for patients treated with or without AC (P>0.05 for all). Toxicities were generally mild to moderate. CONCLUSION: Primary surgery with postoperative radiotherapy yielded excellent local control and acceptable toxicity profile for HNMM. Nevertheless, high rates of distant metastases resulted in limited survival.
format Online
Article
Text
id pubmed-6298389
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62983892018-12-26 Efficacy and safety of primary surgery with postoperative radiotherapy in head and neck mucosal melanoma: a single-arm Phase II study Yao, Ji-Jin Zhang, Fan Zhang, Guang-Shun Deng, Xiao-Wu Zhang, Wang-Jian Lawrence, Wayne R Zou, Lu Zhang, Xiao-Shi Lu, Li-Xia Cancer Manag Res Original Research BACKGROUND: There still remains no well-established treatment strategy for head and neck mucosal melanoma (HNMM). We aim to evaluate the effectiveness and safety of primary surgery with postoperative radiotherapy for this disease. PATIENTS AND METHODS: A single-arm, Phase II clinical trial was conducted at Sun Yat-Sen University Cancer Center. Patients with nonmetastatic, histologically proven HNMM were prospectively enrolled. Patients received primary surgery followed by intensity-modulated radiotherapy with an equivalent dose at 2 Gy per fraction of 65–70 Gy to CTV1 (high-risk regions including tumor bed) and 50–55 Gy to CTV2 (low-risk regions). Additional use of adjuvant chemotherapy (AC) depended on consultation from a multidisciplinary team. This trial is registered with ClinicalTrials.gov, number NCT03138642. RESULTS: A total of 33 patients were enrolled and analyzed between July 2010 and November 2016. There were 18 (54.5%) patients with T3 disease and 15 (45.5%) patients with T4a disease. The median age at diagnosis was 58 years (range 27–83 years), and 61% of the cohort were males. The overall median follow-up duration was 25.3 months (range 5.3–67.1 months). The 3-year overall survival (OS), local relapse-free survival (LRFS), regional relapse-free survival (RRFS), and distant metastasis-free survival (DMFS) rates were 44.4, 91.7, 78.1, and 41.7%, respectively. Patients with T4a disease showed significantly inferior OS (P=0.049) and DMFS (P=0.040) than those with T3 disease. Prophylactic neck radiation (PNR) was nearly associated with superior RRFS (P=0.078). However, there was no significant difference in OS, LRFS, RRFS, and DMFS for patients treated with or without AC (P>0.05 for all). Toxicities were generally mild to moderate. CONCLUSION: Primary surgery with postoperative radiotherapy yielded excellent local control and acceptable toxicity profile for HNMM. Nevertheless, high rates of distant metastases resulted in limited survival. Dove Medical Press 2018-12-14 /pmc/articles/PMC6298389/ /pubmed/30588103 http://dx.doi.org/10.2147/CMAR.S185017 Text en © 2018 Yao et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Yao, Ji-Jin
Zhang, Fan
Zhang, Guang-Shun
Deng, Xiao-Wu
Zhang, Wang-Jian
Lawrence, Wayne R
Zou, Lu
Zhang, Xiao-Shi
Lu, Li-Xia
Efficacy and safety of primary surgery with postoperative radiotherapy in head and neck mucosal melanoma: a single-arm Phase II study
title Efficacy and safety of primary surgery with postoperative radiotherapy in head and neck mucosal melanoma: a single-arm Phase II study
title_full Efficacy and safety of primary surgery with postoperative radiotherapy in head and neck mucosal melanoma: a single-arm Phase II study
title_fullStr Efficacy and safety of primary surgery with postoperative radiotherapy in head and neck mucosal melanoma: a single-arm Phase II study
title_full_unstemmed Efficacy and safety of primary surgery with postoperative radiotherapy in head and neck mucosal melanoma: a single-arm Phase II study
title_short Efficacy and safety of primary surgery with postoperative radiotherapy in head and neck mucosal melanoma: a single-arm Phase II study
title_sort efficacy and safety of primary surgery with postoperative radiotherapy in head and neck mucosal melanoma: a single-arm phase ii study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298389/
https://www.ncbi.nlm.nih.gov/pubmed/30588103
http://dx.doi.org/10.2147/CMAR.S185017
work_keys_str_mv AT yaojijin efficacyandsafetyofprimarysurgerywithpostoperativeradiotherapyinheadandneckmucosalmelanomaasinglearmphaseiistudy
AT zhangfan efficacyandsafetyofprimarysurgerywithpostoperativeradiotherapyinheadandneckmucosalmelanomaasinglearmphaseiistudy
AT zhangguangshun efficacyandsafetyofprimarysurgerywithpostoperativeradiotherapyinheadandneckmucosalmelanomaasinglearmphaseiistudy
AT dengxiaowu efficacyandsafetyofprimarysurgerywithpostoperativeradiotherapyinheadandneckmucosalmelanomaasinglearmphaseiistudy
AT zhangwangjian efficacyandsafetyofprimarysurgerywithpostoperativeradiotherapyinheadandneckmucosalmelanomaasinglearmphaseiistudy
AT lawrencewayner efficacyandsafetyofprimarysurgerywithpostoperativeradiotherapyinheadandneckmucosalmelanomaasinglearmphaseiistudy
AT zoulu efficacyandsafetyofprimarysurgerywithpostoperativeradiotherapyinheadandneckmucosalmelanomaasinglearmphaseiistudy
AT zhangxiaoshi efficacyandsafetyofprimarysurgerywithpostoperativeradiotherapyinheadandneckmucosalmelanomaasinglearmphaseiistudy
AT lulixia efficacyandsafetyofprimarysurgerywithpostoperativeradiotherapyinheadandneckmucosalmelanomaasinglearmphaseiistudy